Clinical Trial Update: Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pemetrexed with LBH589 in advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Farydak (panobinostat)

Snippet

Sponsor: University of Pittsburgh | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED